$HCWB

HCW Biologics (HCWB) is progressing toward filing an IND application in 1H 2027 for its lead T-Cell Engager candidate, HCW11-018b, to treat solid tumors. The FDA provided clear guidance at a recent Type B meeting. Manufacturing of clinical trial material is underway. The company's proprietary TRBC platform technology is used to construct the candidate.

HCW Biologics (HCWB) priced a $1.5M private placement with an existing stockholder, issuing 903,614 units. Each unit includes a pre-funded warrant and a common warrant, subject to stockholder approval. Proceeds will fund clinical trials and general corporate purposes. HCWB stock closed at $1.66, down 8.29%, and was up 1.61% in pre-market trading.

HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Inc. Announces Pricing of $1.5 Million Private Placement MIRAMAR, Fla., September 24, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fus

HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells Agreement includes pre-payment commitments for product sales and distribution of the s

Tenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.

HCW Biologics (HCWB) reported a wider Q2 net loss of $5.2 million versus $1.9 million a year earlier, with licensing revenue rising to $135,568 from $6,550. The company said there is substantial doubt about continuing as a going concern without additional funding. It expects Phase 1 data for HCW9302 in alopecia areata in Q4 2026.

HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results Miramar, FL – August 14, 2026 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on de

Wong Hing C (Chief Executive Officer) purchased 23,210 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.

Flowers Lee (SVP of Business Development) purchased 7,736 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.

HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative